Alpha-glucosidase inhibitors

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

Top

Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369-71. OBJECTIVE To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications.

Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes

Top

Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes. 2009;58(3):701-709. The physiology of counterregulatory responses during hypoglycemia in intensively treated type 2 diabetic subjects is largely unknown.

Treating type 2 diabetes: how safe are current therapeutic agents?

Top

Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents?. Int J Clin Pract. 2009;63(2):321-332. Sulphonylureas (SUs) and biguanides (metformin) are the current mainstays in the treatment of type 2 diabetes (T2DM) and represent the most commonly used oral hypoglycaemic agents (OHAs).

Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program

Top

Kirkman MS, Shankar RR, Shankar S, et al. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care. 2006;29:2095-2101. We investigated whether ameliorating postprandial hyperglycemia with acarbose would prevent or delay progression of diabetes, defined as progression to frank fasting hyperglycemia, in subjects with early diabetes (fasting plasma glucose [FPG] <140 mg/dl and 2-h plasma glucose > or =200 mg/dl).

Pharmacologic prevention or delay of type 2 diabetes mellitus

Top

Anderson DC, Jr. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother. 2005;39:102-109. To evaluate the current data on pharmacologic interventions intended to prevent or delay the onset of type 2 diabetes mellitus.

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance R2

Top

Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects with Impaired Glucose Tolerance R2. Stroke. 2004;35:1073-1078. Impaired glucose tolerance (IGT)-a prediabetic state-is an important risk factor for atherosclerosis.

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting

Top

Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005;28:20-26. OBJECTIVE: To assess the effects of antidiabetic drugs on the risk of heart failure in patients with type 2 diabetes.

Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial

Top

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial. JAMA. 2003;290:486-494. OBJECTIVE: To evaluate the effect of decreasing postprandial hyperglycemia with acarbose, an alpha-glucosidase inhibitor, on the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance (IGT).

Pioglitazone in Type 2 Diabetes Poorly Controlled With a-Glucosidase Inhibitors, Alone or in Combination With Sulfonylureas

Top

Hayashi Y, Miyachi N, Takeuchi T, et al. Clinical evaluation of pioglitazone in patients with type 2 diabetes using a-glucosidase inhibitor and examination of its efficacy profile. Diabetes Obes Metab. 2003;5:58-65. Twenty patients with type 2 diabetes poorly controlled with a-glucosidase inhibitors, alone or in combination with a sulfonylurea, were enrolled in a 16-week, open-label study to receive 30 mg pioglitazone, orally, once a day in addition to their current medications.

1 2 Next